Forte Biosciences Announces HSR Clearance for argenx Tender Offer
FBRX has more than doubled off its 52-week low of $10.11.
Summary
Forte Biosciences disclosed that the HSR waiting period for argenx's tender offer expired on August 18, 2026, satisfying a condition to the merger.
Key Events · M&A and Partnerships · FBRX
-
HSR Waiting Period Expired
The HSR waiting period for argenx's tender offer expired at 11:59 p.m. ET on August 18, 2026, satisfying the regulatory condition in clause (e)(i) of Annex I to the Merger Agreement.
-
Tender Offer Condition Satisfied
The expiration of the HSR waiting period removes a key condition to the tender offer, bringing the $77 per share all-cash acquisition closer to completion.
-
Deal Timeline Advances
The tender offer was commenced on August 6, 2026, and the HSR clearance was obtained on August 18, 2026, with no other regulatory conditions disclosed as outstanding.
Analysis · FBRX · Life Sciences
The HSR waiting period for argenx's $77 per share all-cash tender offer for Forte Biosciences expired on August 18, 2026, satisfying a key regulatory condition. This removes a significant hurdle to closing the $2.2 billion acquisition and moves the deal closer to completion.
At the time of this filing, FBRX was trading at $76.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $10.11 to $77.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.